April 15, 2013 (Vol. 33, No. 8)
Conkwest hired Hans Klingemann, M.D., Ph.D., as CMO and CSO. Dr. Klingemann is a member of the board for Osiris Therapeutics. Previously, he was professor of medicine and director, bone marrow and stem cell transplant program at Tufts Medical Cancer Center.
Amarantus BioScience appointed Mark Benedyk, Ph.D., to its board of directors…Novella Clinical added Jon Gockerman, M.D., as senior medical director for oncology…Hugh Alsop is now CEO of Hatchtech…Curis named Kenneth Pienta, M.D., to its board of directors.
James Taylor joined INC Research as vp, clinical development. He has more than 25 years of experience in the life sciences industry. Most recently, Taylor was vp, global clinical trial management at Pfizer. He also served as global head of outsourcing management at Sanofi-Aventis.
Steve Butcher joined CoCo Therapeutics as COO…Sagent Pharmaceuticals elected James M. Hussey as President…Asylum Research hired Florian Johann as an applications scientist…Spectrum Pharmaceuticals added Lee F. Allen, M.D., Ph.D., as CMO…John LaMattina, Ph.D., joined Ziarco as strategic advisor.
XOMA added Tom Klein as CCO. He joined XOMA from Genentech, where he was vp, business unit head virology and specialty care. Klein served various roles at Roche for 12 years. Before that, he held sales and product management positions at Westwood-Squibb/Bristol Myers-Squibb.
Kymab appointed Duncan Casson, M.D., as chief development officer and Ken Smith to its scientific advisory board…Cytos Biotechnology hired Matthias Alder as evp for corporate development and legal affairs and Cheryl Lassen as vp for clinical development.
Richard W. Pascoe is now CEO at Apricus Biosciences. Formerly, he was CEO at Somaxon Pharmaceuticals. Prior to that, he was svp and COO at ARIAD Pharmaceuticals and was svp in marketing and sales and vp in international sales and marketing at King Pharmaceuticals.
Labrys Biologics added Marcelo Bigal, M.D., Ph.D., as CMO; Michael Chang, Ph.D., as vp of project management; Michele Bronson, Ph.D., as vp of regulatory and quality; Rafael Escandón, Ph.D., as vp of clinical operations; and Henry Stern as executive director of CMC…Teva Pharmaceutical hired Ivana Magovcevic-Liebisch, Ph.D., as svp, head of corporate business development.
Boston Therapeutics appointed Peter Sheehan, M.D., as consulting medical director. He is currently the president of Sheehan Health Management Consulting, president of the NYC Leadership Council of the American Diabetes Association, and a member of the board of the Wound Healing Society.
Cerapedics appointed Antony Koblish to its board of directors…Cell Medica named Kurt Gunter, M.D., as CMO; Jeff Hammel as CFO; and Ross Durland, Ph.D., as svp of development…Argos Therapeutics appointed Jean Lamarre to its board of directors…Nuevolution added Marc Feldmann, Gordon B. Mills, M.D., Ph.D., and Alan Collis, Ph.D., as scientific advisors.
Ironwood elected Benjamin Cravatt, Ph.D., to its pharmaceutical advisory committee. Dr. Cravatt is professor and chairman of the department of chemical physiology and member of the Skaggs Institute for Chemical Biology at The Scripps Research Institute.
Stefan Scherer joined Biocartis as CMO…BioTime appointed Stephen C. Farrell to its board of directors…Jenny Harry, Ph.D., is now CEO at Ondek…Catalent named Ralph Lipp, Ph.D., to its advisory board and Terry Robinson as executive director…Sample6 Technologies added Tim Curran as CEO…Katrine Bosley has joined Genocea Biosciences as an independent director.
Aastrom named Dominick C. Colangelo as president, CEO, and a member of its board of directors. Most recently, he was president and CEO of Promedior. Colangelo has held executive positions in product development, pharmaceutical operations, sales and marketing, and corporate development.
Ignyta appointed Tom Huizinga to its scientific advisory board…Cibiem added Ken Martin as president and CEO…Definiens appointed Ron A. Andrews, Uwe Bicker, Manfred Dietel, Eric F. Glassy, M.D., and Gerd Binnig to its advisory board…BioSig Technologies named Kalyanam Shivkumar, M.D., Ph.D., to its board of directors…Ivan Cohen-Tanugi, M.D., is now CEO at Eyevensys…Deborah S. Hartman, Ph.D., joined Avaxia Biologics as vp, research.
Send your People Announcements to sbhutta@GENengnews.com